



# SAFETY DATA SHEET

## 1. IDENTIFICATION

**Product identifier:** SUPRELORIN® F (deslorelin acetate) 4.7mg Implant

**Manufacturer Name:** Virbac AH, Inc.  
**Address:** P.O. Box 162059  
Fort Worth, TX 76161 USA

**Telephone number:** 1-800-338-3659

**Emergency phone number:** CHEMTREC: (800) 424-9300  
Human Toll-free 833-224-2009  
Animal Toll-free 833-224-2013

**Recommended use:** Animal drug

**Restrictions on use:** Use only as directed.

## 2. HAZARD(S) IDENTIFICATION

**Classification:**

Physical	Health
Not hazardous	Reproductive Toxicity Category 1B

**Label Elements:**

**Warning!**



**Hazard statement(s)**

May damage fertility or the unborn child.

**Precautionary statement(s)**

Obtain special instructions before use.

Do not handle until all safety precautions have been read and understood.

Wear protective clothing and gloves.

IF exposed or concerned: Get medical attention.

Store locked up.

Dispose in accordance with local and national regulations.

**Other Hazards:** None known

## 3. COMPOSITION / INFORMATION ON INGREDIENTS

Chemical name	CAS No.	Concentration
Deslorelin acetate	57773-65-6	10-15%
Hydrogenated palm oil	68514-74-9	Proprietary

## 4. FIRST-AID MEASURES

**Inhalation:** Inhalation is unlikely given the product form. If symptoms develop, get medical attention.

**Skin contact:** Wash skin with soap and water. If irritation or symptoms develop, get medical attention.

**Eye contact:** If eye contact occurs, immediately flush eyes with water while lifting the upper and lower lids. Get medical attention if irritation persists.

**Ingestion:** Ingestion is unlikely given the product form. If swallowed, seek medical attention.

**Most important symptoms/effects, acute and delayed:** Deslorelin is absorbed by inhalation or skin absorption. In males, single doses (micrograms) may lead to an increase in testosterone. Chronic exposure (micrograms) may lead to decreased libido, decreased erections, hot flushes, breast swelling or tenderness, and decreased testicular size. In females, single doses (micrograms) may cause irregular menses. Chronic exposure (micrograms) may lead to decreased libido, hot flushes, irregular menses or annovulation, mood changes, vaginal dryness, headaches, and breast atrophy or enlargement.

**Indication of immediate medical attention and special treatment, if necessary:** Immediate medical attention is generally not required.

## 5. FIRE-FIGHTING MEASURES

**Extinguishing media:** Use water spray, carbon dioxide, dry chemical or foam to extinguish a fire.

**Specific hazards arising from the chemical:** Implants are not a fire hazard but may burn under fire conditions. Combustion products may be hazardous.

**Special protective equipment and precautions for fire-fighters:** Firefighters should wear positive pressure self-contained breathing apparatus and full protective clothing for all fires involving chemicals.

## 6. ACCIDENTAL RELEASE MEASURES

**Personal precautions, protective equipment, and emergency procedures:** Wear appropriate protective clothing and equipment as described in Section 8.

**Environmental Precautions:** Prevent spills from entering sewers and water courses. Report releases as required by local and national authorities.

**Methods and materials for containment and cleaning up:** Pick up and place in appropriate container for disposal. Clean area thoroughly.

## 7. HANDLING AND STORAGE

**Precautions for safe handling:** Avoid contact with eyes, skin and clothing. Wash thoroughly with soap and water after handling.

**Conditions for safe storage, including any incompatibilities:** Store at 2° C to 8°C (refrigerate, do not freeze). Store in a cool dry place. Keep away from children.

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

### Exposure guidelines:

Deslorelin acetate	None Established
Hydrogenated palm oil (as vegetable oil)	5 mg/m <sup>3</sup> (respirable), 15 mg/m <sup>3</sup> (total) TWA OSHA PEL

**Appropriate engineering controls:** No specific measures required for normal handling and use.

### Individual protection measures:

**Respiratory protection:** None needed under normal use conditions.

**Skin protection:** Impervious gloves recommended.

**Eye protection:** None required for normal use.

**Other:** None known.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

**Appearance (physical state, color, etc.):** Solid. Opaque, white to pale yellow cylinder.

**Odor:** None

<b>Odor threshold:</b> Not applicable	<b>pH:</b> Not applicable
<b>Melting point/freezing point:</b> Not applicable	<b>Boiling Point:</b> Not applicable
<b>Flash point:</b> Not applicable	<b>Evaporation rate:</b> Not applicable
<b>Flammability (solid, gas):</b> Not flammable	<b>VOC:</b> Not applicable
<b>Flammable limits: LEL:</b> Not applicable	<b>UEL:</b> Not applicable
<b>Vapor pressure:</b> Not applicable	<b>Vapor density:</b> Not applicable
<b>Relative density:</b> Not available	<b>Solubility(ies):</b> Not available
<b>Partition coefficient: n-octanol/water:</b> Not available	<b>Auto-ignition temperature:</b> Not available
<b>Decomposition temperature:</b> Not available	<b>Viscosity:</b> Not applicable

## 10. STABILITY AND REACTIVITY

**Reactivity:** Not reactive under normal conditions of use.

**Chemical stability:** Stable.

**Possibility of hazardous reactions:** None known.

**Conditions to avoid:** None known.

**Incompatible materials:** Avoid oxidizing agents.

**Hazardous decomposition products:** Thermal decomposition may yield carbon and nitrogen oxides.

## 11. TOXICOLOGICAL INFORMATION

**Acute effects of exposure:**

**Inhalation:** Inhalation is unlikely due to product form.

**Ingestion:** Ingestion is unlikely due to product form.

**Skin contact:** Contact may cause slight irritation. Deslorelin acetate may be absorbed through the skin.

**Eye contact:** Contact may cause irritation.

**Chronic Effects:** Deslorelin acetate is a LHRH agonist and has actions similar to LHRH (GnRH) which is the key mediator in the neuroregulation of the secretion of the gonadotropins, luteinising hormone (LH) and follicle stimulating hormone (FSH). LHRH can modify sexual behavior and function by regulating plasma gonadotropins and sex steroid levels. In males, single doses (micrograms) may lead to an increase in testosterone. Chronic exposure (micrograms) may lead to decreased libido, decreased erections, hot flushes, breast swelling or tenderness, and decreased testicular size. In females, single doses (micrograms) may cause irregular menses. Chronic exposure (micrograms) may lead to decreased libido, hot flushes, irregular menses or annovulation, mood changes, vaginal dryness, headaches, and breast atrophy or enlargement.

**Sensitization:** Components are not sensitizers.

**Germ Cell Mutagenicity:** No adverse effects are expected. Components are not germ cell mutagens.

**Reproductive Toxicity:** No specific data is available. Exposure to deslorelin may cause adverse reproductive effects. Refer to chronic effects in this section.

**Carcinogenicity:** None of the components are listed as carcinogens by IARC, NTP or OSHA .

**Acute Toxicity Values:** No data available.

## 12. ECOLOGICAL INFORMATION

**Ecotoxicity values:** No data available

**Persistence and degradability:** No data available.

**Bioaccumulative potential:** No data available

**Mobility in soil:** No data is available.

**Other adverse effects:** None known.

### 13. DISPOSAL CONSIDERATIONS

Dispose in accordance with all local, state and federal regulations. No specific disposal method is recommended.

### 14. TRANSPORT INFORMATION

	UN Number	Proper shipping name	Hazard Class	Packing Group	Environmental Hazard
DOT		Not Regulated			No
IMDG		Not Regulated			No
IATA		Not Regulated			No

**Transport in bulk (according to Annex II of MARPOL 73/78 and the IBC Code):** Not applicable – product is transported only in packaged form.

**Special precautions:** None known.

### 15. REGULATORY INFORMATION

**Safety, health, and environmental regulations specific for the product in question.**

**CERCLA:** This product is not subject to CERCLA release reporting. Many states have more stringent release reporting requirements. Report spills as required under federal, state and local regulations.

**SARA Hazard Category (311/312):** Refer to Section 2 for the OSHA Hazard Classification.

**EPA SARA 313:** This product contains the following chemicals regulated under SARA Title III, section 313:  
None

**EPA TSCA Inventory:** This product is a drug and not subject to TSCA.

### 16. OTHER INFORMATION

**SDS Revision History:** Major update. Revisions to all sections.

**Date of preparation:** April 20, 2023

SUPRELORIN® is a registered trademark of Virbac (Australia) Pty Ltd

The information and recommendations presented in this SDS are based on sources believed to be accurate. Neither Virbac AH, Inc. nor any of its affiliated companies assumes any liability for the accuracy or completeness of this information. It is the user's responsibility to determine the suitability of the material for their particular purposes. In particular, we make **NO WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED**, with respect to such information, and we assume no liability resulting from its use. Users should ensure that any use or disposal of the material is in accordance with applicable Federal, State, and local laws and regulations.